Epidemiology of viral hepatitis among European drug users - A Danes perspective

Suchtmedizin in Forschung und Praxis

Volumn 11, Issue 5, 2009, Pages 214-219

  Christensen, Peer Brehm ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Incidence; Injecting drug use; Mortality; Prevalence; Viral hepatitis

Indexed keywords

CONFERENCE PAPER; EUROPE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; MORTALITY; PREVALENCE; VIRUS HEPATITIS;

EID: 70349658706     PISSN: 14375567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Aceijas C, Rhodes T (2007): Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 18(5): 352-358 (Pubitemid 47374507)
2. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R (2005): Hepatitis C virus infection and injection drug users: prevention, riskfactors, and treatment. Clin Infect Dis 40 (Suppl 5): S330-5 (Pubitemid 40490220)
3. Butler T, Kariminia A, Levy M, Kaldor J (2004): Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol 19(12): 1119-1122 (Pubitemid 40228500)
4. Christensen PB (2000): Bloodborne viral infections in Funen. PhD thesis, University of Southern Denmark, Odense, Denmark, pp. 1-142
5. Christensen PB, Hammerby E, Smith E, Bird SM (2006): Mortality among Danish drug users released from prison. International Journal of Prisoner Health 2(1): 13-19 (Pubitemid 44106804)
6. Christensen PB, Krarup HB, Møller A, Laursen AL, Kjaer MS, Orholm M, Lindberg J, Groenbaek K, Kromann-Andersen H, Weis N (2006): Liver biopsy performance and histological findings among patients with chronic viral hepatitis - a Danish database study. Scand J Infect Dis 39(3): 245-249 (Pubitemid 46322809)
7. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J (2000): Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 16(11): 1043-1049 (Pubitemid 34815008)
8. Christensen PB, Kringsholm B, Banner J, Thomsen JL, Cowan S, Stein GF, Jurgensen GW, Grasaasen K, Georgsen J, Pedersen C (2006): Surveillance of HIV and viral hepatitis by analysis of samples from drug related deaths. Eur J Epidemiol 21(5): 383-387 (Pubitemid 44050809)
9. Darke S, Zador D (1996): Fatal heroin 'overdose': a review. Addiction 91(12): 1765-1772
10. Dienstag JL, McHutchison JG (2006): American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130(1): 231-264 (Pubitemid 43049856)
11. Duberg A, Janzon R, Back E, Ekdahl K, Blaxhult A (2008): The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 13(21): 18882
12. Dubois-Arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, Jeannin A, Schnoz D, Gervasoni JP (2008): Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. Euro Surveill 13(21): 18881
13. Esteban JI, Sauleda S, Quer J (2008): The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48(1): 148-162 (Pubitemid 350191999)
14. EASL (European Association For The Study Of The Liver) (2009): EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50(2): 227-242
15. EMCDDA (2004): Annual Report 2003 - The State of the Drugs Problem in the European Union and Norway. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction
16. EMCDDA (2008): Annual report 2008 - The state of the drugs problem in Europe. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction
17. ]Fisker N, Christensen PB (2001): Short versus standard schedule Hepatitis B vaccination to injecting drug users in prisons and drug treatment centers. Rev esp sanid penit 3: 55-64
18. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, Yu XF (2004): Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 33(1): 182-188 (Pubitemid 38500175)
19. Ghodse H, Oyefeso A, Kilpatrick B (1998): Mortality of drug addicts in the United Kingdom 1967-1993. Int J Epidemiol 27(3): 473-478 (Pubitemid 28336977)
20. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR (2005): Transmission of hepatitis C virus among HIV-positive homosexual men and response toa 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 40(1):41-46 (Pubitemid 41233203)
21. Grinde B, Stene JK, Sharma B, Hoel T, Jensenius M, Skaug K (1997): Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers - infection by needle sharing? J Med Virol 53(1): 69-75
22. Haastrup S, Jepsen PW (1984): Seven year follow-up of 300 young drug abusers. Acta Psychiatr Scand 70(5): 503-509 (Pubitemid 15182225)
23. Hagan H, Des J, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, Flom PL (2007): HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 18(5): 341-351 (Pubitemid 47374503)
24. Hutchinson SJ, Roy KM, Wadd S, Bird SM, Taylor A, Anderson E, Shaw L, Codere G, Goldberg DJ (2006): Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scott Med J 51(2): 8-15
25. Jagger J, Kretzschmar M, Postma M, Wiessing L (2004): Hepatitis C and injecting drug use: mpact, cost and policy options. Luxembourg, European Monitoring Centre for Drugs and Drug Addiction. pp. 1-389
26. Krarup HB, Drewes, A.M., & Madsen, P.H. (1998). A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 58(5): 415-422
27. Krarup HB, Moller JM, Christensen PB, Fuglsang T, Ingerslev J, Arnfred T, Madsen PH (2000): Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 7(6): 435-439
28. Levine OS, Vlahov D, Nelson KE (1994): Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev 16 418-436
29. Lugoboni F, Migliozzi S, Mezzelani P, Pajusco B, Ceravolo R, Quaglio G (2004): Progressive decrease of hepatitis B in a cohort of drug users followed over a period of 15 years: the impact of anti-HBV vaccination. Scand J Infect Dis 36(2): 131-133 (Pubitemid 38313040)
30. Mathei C, Buntinx F, van DP (2002): Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 9(3): 157-173
31. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL (2008): Limited uptake of hepatitis C treatment among injection drug users. J. Community Health 33(3): 126-133
32. Mösner B, Jørgensen T, Skamling M, Pedersen C, Christensen PB (2008): Outreach Screening Of Drug Users With Fibroscan® Identifies A High Proportion Of Severe Fibrosis Not Previously Recognized. J Hepatol 48 (Suppl. 2): S276 (abstract 740)
33. Mösner B, Jørgensen T, Skamling M, Pedersen C, Christensen PB (2009): Hepatitis B Vaccination Reduces The Risk Of Developing Chronic Hepatitis B Among Drug Users - Even Without Protecting Level Of Anti-HBs. J Hepatol 50 (Suppl. 1): S141 (abstract 369)
34. Omland LH, Krarup HB, Jepsen P, Georgsen J, Harritshøj LH, Riisom K, Jacobsen SE, Schouenborg P, Christensen PB, Sorensen HT, Obel N (2009): Mortality in patients with chronic and cleared Hepatitis C viral infection: A population-based cohort study. J Viral Hepat (in press)
35. Pellicelli AM, Barbara G, Barbarini G, Soccorsi F (2008): Management of chronic hepatitis in drug addicts: a systematic review. Clin Ter 159(1): 41-49
36. Poynard T, Bedossa P, Opolon P (1997): Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349(9055): 825-832
37. Rotily M, Weilandt C, Bird SM, Kall K, van Haastrecht HJ, Iandolo E, Rousseau S (2001): Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Public Health 11(3): 243-250 (Pubitemid 32912154)
38. Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L (2002): Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 129(3): 577-585 (Pubitemid 36157682)
39. Roy KM, Goldberg DJ, Wilson K, Cameron SO (2008): Vaccination induced immunity to the hepatitis B virus among high-risk groups in Glasgow 1993-2001: evaluating the effectiveness of the United Kingdom's selective immunisation policy. Scott Med J 53(4): 13-17
40. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des J, Flom PL, Strauss S (2007): Non-injection drug useand Hepatitis C Virus: a systematic review. Drug Alcohol Depend 89(1): 1-12 (Pubitemid 46602869)
41. Seeff LB, Miller RN, Rabkin CS, Buskell BZ, Straley-Eason KD, Smoak BL, Johnson LD, Lee SR, Kaplan EL (2000): 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132(2): 105-111 (Pubitemid 30044176)
42. Spada E, Genovese D, Tosti ME, Mariano A, Cuccuini M, Proietti L, Giuli CD, Lavagna A, Crapa GE, Morace G, Taffon S, Mele A, Rezza G, Rapicetta M (2005): An outbreak of hepatitis A virus infection with a high case-fatality rate among injecting drug users. J Hepatol 43(6): 958-964 (Pubitemid 41627980)
43. Stimson GV, Hickman M, Quirk A, Frischer M, Taylor C (eds): (2009a): Estimating the prevalence of problem drug use in Europe. Lisabon, pp. 1-271
44. van den Berg CH, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M (2007): Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 22(3): 183-193 (Pubitemid 46481325)
45. WHO fact sheet 164 Hepatitis C (2009b): www.who.int/mediacentre/ factsheets/fs164/en/ (accessed 29/06/2009)